ASH 2020 | Targeted agents are desperately needed in myelofibrosis
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the development of individualized treatment plans for patients with myeloproliferative neoplasms; the topic of a satellite symposium he is part of at ASH 2020. He highlights the need for the development of therapies that would specifically target malignant clones in myelofibrosis. One key focus for future therapy development is likely to be the development of antibodies against mutated calreticulin seen in 30-40% cases of myelofibrosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
